diagonal
spacer

VPHM Briefing

Denis at [D] Investor is covering the latest VPHM news on his blog. The stock is being hammered after news that ViroPharma's flagship Vancocin drug might be toppled by India's Cipla and Akron which are working on generic versions of the drug. Overall, however, Denis seems to see VPHM as a value stock.



2 Responses to “VPHM Briefing”


By Anonymous on March 28th, 2006 at 10:44 am

No firm has been named to be working to produce a generic so I am at a loss as to your news sources on this drug.

By Shelly Adams on January 4th, 2008 at 1:50 pm

This is really bad news. VPHM is already a second-string pharmaceutical company. I hate when overseas companies jack our loot. Wizetrade is pretty concerned about this stock also.

Leave a Comment


Comments: